(Q33330233)

English

Intermittent 2-hour-infusion of cladribine as first-line therapy or in first relapse of progressive advanced low-grade and mantle cell lymphomas

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

25 July 2017

Intermittent 2-hour-infusion of cladribine as first-line therapy or in first relapse of progressive advanced low-grade and mantle cell lymphomas (English)

1 reference

Europe PubMed Central

25 July 2017

author name string

Rummel MJ

1

1 reference

Europe PubMed Central

25 July 2017

Chow KU

2

1 reference

Europe PubMed Central

25 July 2017

Jäger E

3

1 reference

Europe PubMed Central

25 July 2017

Leimer L

4

1 reference

Europe PubMed Central

25 July 2017

Hossfeld DK

5

1 reference

Europe PubMed Central

25 July 2017

Bergmann L

6

1 reference

Europe PubMed Central

25 July 2017

Peters HD

7

1 reference

Europe PubMed Central

25 July 2017

Hansmann ML

8

1 reference

Europe PubMed Central

25 July 2017

Meyer A

9

1 reference

Europe PubMed Central

25 July 2017

Hoelzer D

10

1 reference

Europe PubMed Central

25 July 2017

Mitrou PS

11

1 reference

Europe PubMed Central

25 July 2017

publication date

1 September 1999

1 reference

Europe PubMed Central

25 July 2017

Leukemia & Lymphoma

1 reference

Europe PubMed Central

25 July 2017

35

1 reference

Europe PubMed Central

25 July 2017

129-138

1 reference

Europe PubMed Central

25 July 2017

1-2

1 reference

Europe PubMed Central

25 July 2017

Cladribine (2-chlorodeoxyadenosine)

1 reference

https://api.crossref.org/works/10.3109%2F10428199909145712

21 January 2018

Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to nondividing human lymphocytes

1 reference

https://api.crossref.org/works/10.3109%2F10428199909145712

21 January 2018

2'-Chlorodeoxyadenosine: evaluation of a novel predominantly lymphocyte selective agent in lymphoid malignancies

1 reference

https://api.crossref.org/works/10.3109%2F10428199909145712

21 January 2018

Intermittent infusion of cladribine (CdA) in previously treated patients with low-grade non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.3109%2F10428199909145712

21 January 2018

A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project

1 reference

https://api.crossref.org/works/10.3109%2F10428199909145712

21 January 2018

2-chlorodeoxyadenosine (2-CDA) therapy in previously untreated patients with follicular stage III-IV non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.3109%2F10428199909145712

21 January 2018

2-Chlorodeoxyadenosine as initial therapy for advanced low grade lymphomas

1 reference

https://api.crossref.org/works/10.3109%2F10428199909145712

21 January 2018

Cladribine for untreated or early low-grade non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.3109%2F10428199909145712

21 January 2018

Identifiers

10.3109/10428199909145712

1 reference

Europe PubMed Central

25 July 2017

1 reference

Europe PubMed Central

25 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33330233&oldid=1509339193"